Table III.

Multivariate analyses with bootstrap analysis of time-dependent covariates after the first cycle but within the first 12 weeks (week 4–12) on first-line treatment of patients with mRCC stratified by TKI and IL2-based immunotherapy. N = 588.

	Multivariate analysis a			Bootstrap analysisb
	HR	95% CI	p-Value	Mean HR	95% CI	p-Value
Baseline IMDC risk group
Favourable versus poor	0.33	0.23–0.49	<0.0001	0.35	0.24–0.49	<0.0001
Intermediate versus poor	0.56	0.45–0.71	<0.0001	0.57	0.45–0.71	<0.0001
Biomarkers within 12 weeks
Sodium ≥ LLN	0.63	0.49–0.80	0.0002	0.62	0.47–0.83	0.001
LDH ≤1.5 times ULN	0.45	0.31–0.66	<0.0001	0.45	0.28–0.74	0.002
Platelets < LLN	0.66	0.48–0.91	0.0112	0.67	0.50–0.90	0.009
Neutrophils < LLN	0.75	0.57–0.98	0.0352	0.75	0.58–0.97	0.031
Systolic BP ≥140 mmHg	0.70	0.56–0.87	0.0014	0.67	0.55–0.82	0.0001

^aTime-dependent Cox proportional hazard model; ^b300 samples. BP, blood pressure; CI, confidence interval; HR, hazard ratio; IL2, interleukin-2; IMDC, International mRCC Database Consortium; LDH, lactate dehydrogenase; LLN, lower level of normal; mRCC, metastatic renal cell carcinoma; TKI, tyrosine kinase inhibitor; ULN, upper level of normal.